688177 百奥泰
已收盘 05-11 15:00:02
资讯
新帖
简况
百奥泰（688177）披露关于转让药品品种权益及相关资产与业务的议案获通过，5月6日股价下跌1.8%
证券之星 · 05-06
百奥泰（688177）披露关于转让药品品种权益及相关资产与业务的议案获通过，5月6日股价下跌1.8%
每周股票复盘：百奥泰（688177）股东户数增7.75%
证券之星 · 05-02
每周股票复盘：百奥泰（688177）股东户数增7.75%
百奥泰（688177）2026年一季报简析：增收不增利
证券之星 · 04-29
百奥泰（688177）2026年一季报简析：增收不增利
图解百奥泰年报：第四季度单季净利润同比增长25.45%
证券之星 · 04-28
图解百奥泰年报：第四季度单季净利润同比增长25.45%
每周股票复盘：百奥泰（688177）拟4.5亿元转让贝塔宁品种权益
证券之星 · 04-26
每周股票复盘：百奥泰（688177）拟4.5亿元转让贝塔宁品种权益
百奥泰拟4.5亿元出售贝塔宁权益 乐普药业接盘
中国经营报 · 04-15
百奥泰拟4.5亿元出售贝塔宁权益 乐普药业接盘
诺和诺德与OpenAI达成战略合作；再生元牵手Telix
21世纪经济报道 · 04-15
诺和诺德与OpenAI达成战略合作；再生元牵手Telix
百奥泰（688177）披露BAT3306联合BAT8008治疗晚期实体瘤获临床试验批准，4月3日股价下跌2.8%
证券之星 · 04-03
百奥泰（688177）披露BAT3306联合BAT8008治疗晚期实体瘤获临床试验批准，4月3日股价下跌2.8%
百奥泰(688177.SH)：BAT3306联合BAT8008治疗晚期实体瘤获得药物临床试验批准通知书
智通财经网 · 04-02
百奥泰(688177.SH)：BAT3306联合BAT8008治疗晚期实体瘤获得药物临床试验批准通知书
每周股票复盘：百奥泰（688177）获STADA支付250万美元里程碑款
证券之星 · 03-29
每周股票复盘：百奥泰（688177）获STADA支付250万美元里程碑款
百奥泰最新公告：收到STADA支付的250万美元里程碑款
证券之星 · 03-26
百奥泰最新公告：收到STADA支付的250万美元里程碑款
百奥泰宣布与Intas制药就戈利木单抗生物类似药Bat2506达成印度独家商业化许可协议 深化战略合作
美股速递 · 03-23
百奥泰宣布与Intas制药就戈利木单抗生物类似药Bat2506达成印度独家商业化许可协议 深化战略合作
“十五五”将谋划约千个紧密型县域医共体建设；先维盈 获批上市
21世纪经济报道 · 03-09
“十五五”将谋划约千个紧密型县域医共体建设；先维盈 获批上市
百奥泰公布国际专利申请：“抗FRα抗体药物偶联物和VEGF拮抗剂在治疗肿瘤中的应用”
证券之星 · 03-07
百奥泰公布国际专利申请：“抗FRα抗体药物偶联物和VEGF拮抗剂在治疗肿瘤中的应用”
百奥泰(688177.SH)：BAT8008联合BAT1006及曲妥珠单抗治疗晚期实体瘤获得药物临床试验批准通知书
智通财经网 · 03-06
百奥泰(688177.SH)：BAT8008联合BAT1006及曲妥珠单抗治疗晚期实体瘤获得药物临床试验批准通知书
百奥泰(688177.SH)：乌司奴单抗注射液获上市批准
智通财经网 · 03-03
百奥泰(688177.SH)：乌司奴单抗注射液获上市批准
百奥泰（688177）披露2025年度业绩快报，2月26日股价下跌1.78%
证券之星 · 02-26
百奥泰（688177）披露2025年度业绩快报，2月26日股价下跌1.78%
百奥泰(688177.SH)2025年度归母净亏损3.36亿元
智通财经 · 02-26
百奥泰(688177.SH)2025年度归母净亏损3.36亿元
百奥泰(688177.SH)：达尔扑拜单抗注射液(BAT4406F)上市许可申请获得受理
智通财经 · 02-24
百奥泰(688177.SH)：达尔扑拜单抗注射液(BAT4406F)上市许可申请获得受理
百奥泰（688177）披露Gotenfia（戈利木单抗注射液）获欧洲EMA上市批准的公告，2月24日股价下跌0.68%
中金财经 · 02-24
百奥泰（688177）披露Gotenfia（戈利木单抗注射液）获欧洲EMA上市批准的公告，2月24日股价下跌0.68%
加载更多
公司概况
公司名称：
百奥泰生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2020-02-21
主营业务：
百奥泰生物制药股份有限公司的主营业务是创新药和生物类似药的研发。公司的主要产品是自身免疫药物、抗肿瘤药物。公司被认定为国家高新技术企业、国家工业企业知识产权运用试点企业、国家知识产权优势企业、广东省新型研发机构、广东省工程技术研究中心、广东省工程实验室、广东省企业技术中心、广东省制造业单项冠军企业。
发行价格：
32.76
{"stockData":{"symbol":"688177","market":"SH","secType":"STK","nameCN":"百奥泰","latestPrice":20.35,"timestamp":1778482802000,"preClose":20.04,"halted":0,"volume":6958354,"delay":0,"changeRate":0.0155,"floatShares":413999999,"shares":413999999,"eps":-0.943,"marketStatus":"已收盘","change":0.31,"latestTime":"05-11 15:00:02","open":20.05,"high":20.39,"low":19.2,"amount":138000000,"amplitude":0.0594,"askPrice":20.36,"askSize":6,"bidPrice":20.35,"bidSize":70,"shortable":0,"etf":0,"ttmEps":-0.943,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778549400000},"marketStatusCode":5,"adr":0,"adjPreClose":20.04,"symbolType":"stock_kcb","openAndCloseTimeList":[[1778463000000,1778470200000],[1778475600000,1778482800000]],"highLimit":22.04,"lowLimit":18.04,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":414080000,"isCdr":false,"pbRate":37.6,"roa":"--","roe":"--","epsLYR":-0.8,"committee":0.367491,"marketValue":8427000000,"turnoverRate":0.0168,"status":0,"afterMarket":{"amount":0,"volume":0,"close":20.35,"buyVolume":0,"sellVolume":0,"time":1778484837558,"indexStatus":"已收盘 05-11 15:30:00","preClose":20.04},"floatMarketCap":8427000000},"requestUrl":"/m/hq/s/688177","defaultTab":"news","newsList":[{"id":"2633390184","title":"百奥泰（688177）披露关于转让药品品种权益及相关资产与业务的议案获通过，5月6日股价下跌1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633390184","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633390184?lang=zh_cn&edition=full","pubTime":"2026-05-06 18:50","pubTimestamp":1778064627,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，百奥泰报收于20.23元，较前一交易日下跌1.8%，最新总市值为83.77亿元。公告显示，公司于2026年4月30日召开第二次临时股东会，审议通过了《关于转让药品品种权益及相关资产与业务的议案》。出席会议的股东及代理人共114人，代表有表决权股份288,959,575股，占公司总表决权股份的69.7835%。该议案为普通决议议案，已获出席会议股东所持有效表决权过半数通过，表决结果为同意285,349,592股，占98.7507%；反对3,606,883股，占1.2482%；弃权3,100股，占0.0011%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600032670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632640905","title":"每周股票复盘：百奥泰（688177）股东户数增7.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632640905","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632640905?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:52","pubTimestamp":1777668729,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，百奥泰报收于20.6元，较上周的22.22元下跌7.29%。本周，百奥泰4月27日盘中最高价报22.58元。业绩披露要点：2026年一季报显示，百奥泰归母净利润为-1.52亿元，同比下降62.68%。股本股东变化截至2026年3月31日，百奥泰股东户数为9898.0户，较2025年12月31日增加712.0户，增幅7.75%。表决结果为同意285,349,592股，占98.7507%；反对3,606,883股，占1.2482%；弃权3,100股，占0.0011%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631741530","title":"百奥泰（688177）2026年一季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2631741530","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631741530?lang=zh_cn&edition=full","pubTime":"2026-04-29 07:53","pubTimestamp":1777420434,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期百奥泰发布2026年一季报。根据财报显示，百奥泰增收不增利。其中，毛利率81.34%，同比增5.65%，净利率-60.35%，同比减33.57%，销售费用、管理费用、财务费用总计9730.62万元，三费占营收比38.68%，同比增3.41%，每股净资产0.54元，同比减63.54%，每股经营性现金流0.11元，同比减42.59%，每股收益-0.37元，同比减60.87%证券之星价投圈财报分析工具显示：业务评价：去年的净利率为-35.49%，算上全部成本后，公司产品或服务的附加值不高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900024272.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630319027","title":"图解百奥泰年报：第四季度单季净利润同比增长25.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630319027","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630319027?lang=zh_cn&edition=full","pubTime":"2026-04-28 01:45","pubTimestamp":1777311959,"startTime":"0","endTime":"0","summary":"证券之星消息，百奥泰2025年年报显示，当年度公司主营收入9.35亿元，同比上升25.84%；归母净利润-3.32亿元，同比上升34.95%；扣非净利润-4.26亿元，同比上升23.38%；其中2025年第四季度，公司单季度主营收入2.52亿元，同比上升55.58%；单季度归母净利润-1.08亿元，同比上升25.45%；单季度扣非净利润-1.47亿元，同比上升2.65%；负债率83.56%，投资收益83.39万元，财务费用1748.1万元，毛利率78.91%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800004856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630480802","title":"每周股票复盘：百奥泰（688177）拟4.5亿元转让贝塔宁品种权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2630480802","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630480802?lang=zh_cn&edition=full","pubTime":"2026-04-26 05:20","pubTimestamp":1777152023,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，百奥泰报收于22.22元，较上周的23.03元下跌3.52%。本周，百奥泰4月20日盘中最高价报23.27元。本周关注点公司公告汇总：百奥泰拟向乐普药业转让贝塔宁品种权益及相关资产，交易总金额为4.5亿元。公司公告汇总百奥泰生物制药股份有限公司拟向乐普药业股份有限公司转让贝塔宁品种权益及相关资产与业务，交易总金额（含税）为人民币4.5亿元，分五期支付，并按年度净销售额的个位数百分比收取销售分成，最长分成期为10年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600002329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627406558","title":"百奥泰拟4.5亿元出售贝塔宁权益 乐普药业接盘","url":"https://stock-news.laohu8.com/highlight/detail?id=2627406558","media":"中国经营报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627406558?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:14","pubTimestamp":1776233640,"startTime":"0","endTime":"0","summary":"4月14日晚间，百奥泰发布公告称，公司拟以4.5亿元（含税）向乐普医疗控股子公司乐普药业股份有限公司转让贝塔宁品种权益及相关资产与业务，并签署《贝塔宁制剂及原料药品种转让协议》。据百奥泰公告披露，2025年度贝塔宁的销售收入占公司营业总收入比重较小，本次转让不会对公司正常生产经营造成重大不利影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-15/doc-inhuqfve3511738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627045478","title":"诺和诺德与OpenAI达成战略合作；再生元牵手Telix","url":"https://stock-news.laohu8.com/highlight/detail?id=2627045478","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627045478?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:01","pubTimestamp":1776211308,"startTime":"0","endTime":"0","summary":"政策动向国家医疗保障局持续开展定点医药机构违法违规使用医保基金自查自纠工作国家医疗保障局近日在全国范围内组织开展2026年定点医药机构违法违规使用医保基金自查自纠工作。自查自纠聚焦重点领域“逐渐细化、持续深化”。在既往心血管内科、骨科、血液净化、康复、医学影像、临床检验、肿瘤、麻醉、重症医学等9个重点领域的基础上，本年度进一步将口腔、内分泌、精神医学3个领域纳入自查自纠范围。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705224747.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705224747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","NVO","600513","688177","LU0154236417.USD","BK4532","NVOX","NVOH","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","301087","REGN","BK4599","BK4007","603087","600196","300558","LU1093756168.USD","BK4588","02196","002437","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624651552","title":"百奥泰（688177）披露BAT3306联合BAT8008治疗晚期实体瘤获临床试验批准，4月3日股价下跌2.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624651552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624651552?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:06","pubTimestamp":1775210782,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，百奥泰报收于22.56元，较前一交易日下跌2.8%，最新总市值为93.42亿元。百奥泰生物制药股份有限公司近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意公司研发的BAT3306注射液联合注射用BAT8008在晚期实体瘤患者中开展临床试验。BAT3306为帕博利珠单抗的生物类似药，属于PD-1免疫检查点抑制剂；BAT8008为靶向Trop-2的抗体药物偶联物，拟用于实体肿瘤治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300035007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624774145","title":"百奥泰(688177.SH)：BAT3306联合BAT8008治疗晚期实体瘤获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2624774145","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624774145?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:54","pubTimestamp":1775123652,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰 发布公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研药品BAT3306注射液联合注射用BAT8008用于治疗晚期实体瘤患者的临床试验申请获得批准。帕博利珠单抗是一种人源化单克隆抗体药物，属于免疫检查点抑制剂。BAT8008是百奥泰开发的靶向Trop2的抗体药物偶联物，拟开发用于实体肿瘤治疗。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百奥泰(688177.SH)：BAT3306联合BAT8008治疗晚期实体瘤获得药物临床试验批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623333496","title":"每周股票复盘：百奥泰（688177）获STADA支付250万美元里程碑款","url":"https://stock-news.laohu8.com/highlight/detail?id=2623333496","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623333496?lang=zh_cn&edition=full","pubTime":"2026-03-29 04:43","pubTimestamp":1774730588,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，百奥泰报收于22.29元，较上周的22.08元上涨0.95%。本周，百奥泰3月27日盘中最高价报22.46元。协议首付款及里程碑款总金额最高达1.575亿美元，包括1000万美元首付款和累计不超过1.475亿美元的里程碑付款，以及基于净销售额的两位数百分比分成。公司近日收到STADA支付的250万美元里程碑款，实际到账金额扣除银行手续费。截至公告日，BAT2506已获欧洲EMA批准上市，商品名为Gotenfia，并已向中国NMPA、美国FDA、巴西ANVISA提交上市申请，目前处于评审中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900001174.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622685631","title":"百奥泰最新公告：收到STADA支付的250万美元里程碑款","url":"https://stock-news.laohu8.com/highlight/detail?id=2622685631","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622685631?lang=zh_cn&edition=full","pubTime":"2026-03-26 18:10","pubTimestamp":1774519821,"startTime":"0","endTime":"0","summary":"百奥泰(688177.SH)公告称，公司近日收到STADA就BAT2506(戈利木单抗)注射液授权许可协议支付的250万美元里程碑付款(扣除银行手续费前)。该协议于2024年5月28日签署，授予STADA在欧盟、英国、瑞士等欧洲国家的独占商业化权益，首付款及里程碑款总额最高达1.575亿美元，并含净销售额两位数百分比的收入分成。目前，BAT2506已获欧洲EMA批准上市，商品名为Gotenfia，并已向中国NMPA、美国FDA、巴西ANVISA提交上市申请，正在评审中。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600034336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154213626","title":"百奥泰宣布与Intas制药就戈利木单抗生物类似药Bat2506达成印度独家商业化许可协议 深化战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1154213626","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154213626?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:47","pubTimestamp":1774266444,"startTime":"0","endTime":"0","summary":"百奥泰（Bio-Thera Solutions）近日宣布，通过与Intas制药达成印度独家商业化及许可协议，进一步拓展双方就戈利木单抗（商品名：Simponi®）生物类似药Bat2506的合作关系。该协议标志着两家公司在生物制药领域战略协作的深化，将为印度市场提供高品质的肿瘤免疫治疗新选择。\nBat2506作为戈利木单抗的生物类似药，其研发进展备受行业关注。此次合作将充分发挥Intas制药在印度市场的渠道优势，结合百奥泰先进的生物药研发技术，加速创新疗法惠及更多患者。协议条款涵盖Bat2506在印度的独家商业化权益，凸显了双方对产品市场潜力的共同信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618113692","title":"“十五五”将谋划约千个紧密型县域医共体建设；先维盈 获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2618113692","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618113692?lang=zh_cn&edition=full","pubTime":"2026-03-09 08:07","pubTimestamp":1773014820,"startTime":"0","endTime":"0","summary":"这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！政策动向国家卫健委：“十五五”期间将谋划1000个左右紧密型县域医共体建设3月7日，十四届全国人大 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260309/c675145878.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260309/c675145878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["LU2488822045.USD","LU1969619763.USD","BK0060","LU1064131003.USD","LU1820825898.SGD","LU1064130708.USD","LU2495084118.USD","BK0012","BK0196","BK0188","LU1997244956.HKD","LU2328871848.SGD","LU1781817850.SGD","LU1328615791.USD","LU1146622755.USD","LU1580142542.USD","LU1997245094.SGD","LU2097828474.EUR","LU2097828631.EUR","LU0405327148.USD","LU2097828557.USD","LU1997245177.USD","BK0028","LU2097828805.USD","LU2580892862.HKD","BK0033","LU0405327494.USD","600276","LU1655091616.SGD","BK0183","BK0239","002653","LU2148510915.USD","BK0077","LU1255011170.USD","LU2289578879.USD","LU2097828714.EUR","LU2580892789.USD","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617653589","title":"百奥泰公布国际专利申请：“抗FRα抗体药物偶联物和VEGF拮抗剂在治疗肿瘤中的应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2617653589","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617653589?lang=zh_cn&edition=full","pubTime":"2026-03-07 05:44","pubTimestamp":1772833467,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示百奥泰（688177）公布了一项国际专利申请，专利名为“抗FRα抗体药物偶联物和VEGF拮抗剂在治疗肿瘤中的应用”，专利申请号为PCT/CN2025/116967，国际公布日为2026年3月5日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来百奥泰已公布的国际专利申请5个，与去年同期持平。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了3.49亿元，同比减13.34%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030700002602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617684443","title":"百奥泰(688177.SH)：BAT8008联合BAT1006及曲妥珠单抗治疗晚期实体瘤获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2617684443","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617684443?lang=zh_cn&edition=full","pubTime":"2026-03-06 19:11","pubTimestamp":1772795462,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰 发布公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研药品BAT8008联合BAT1006及曲妥珠单抗用于治疗HER2阳性晚期实体瘤的临床试验申请获得批准。BAT8008是百奥泰开发的靶向Trop2的抗体药物偶联物，拟开发用于实体肿瘤治疗。BAT1006是ADCC增强的单抗，其招募NK等杀伤细胞的能力更强，对肿瘤细胞具有更强的杀伤作用。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411103.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百奥泰(688177.SH)：BAT8008联合BAT1006及曲妥珠单抗治疗晚期实体瘤获得药物临床试验批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616312582","title":"百奥泰(688177.SH)：乌司奴单抗注射液获上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2616312582","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616312582?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:28","pubTimestamp":1772526488,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰 公告，公司近日收到了英国药品和健康产品管理局签发的关于Usymro上市批准通知。公告显示，BAT2206是百奥泰根据中国NMPA、美国FDA、欧洲EMA生物类似药相关指导原则开发的乌司奴单抗注射液，乌司奴单抗是一款靶向白细胞介素IL-12和IL-23共有的p40亚基的全人源单克隆抗体。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百奥泰(688177.SH)：乌司奴单抗注射液获上市批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614290023","title":"百奥泰（688177）披露2025年度业绩快报，2月26日股价下跌1.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614290023","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614290023?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:56","pubTimestamp":1772117772,"startTime":"0","endTime":"0","summary":"截至2026年2月26日收盘，百奥泰报收于23.24元，较前一交易日下跌1.78%，最新总市值为96.23亿元。该股当日开盘23.68元，最高23.74元，最低23.24元，成交额达4466.97万元，换手率为0.46%。近日，百奥泰生物制药股份有限公司发布2025年度业绩快报，营业总收入93,368.50万元，同比增长25.64%。归属于母公司所有者的净利润为-33,644.09万元，较上年同期减亏17,386.29万元。总资产226,665.76万元，较年初增长2.77%；归属于母公司的所有者权益37,153.08万元，较年初下降47.53%。主要原因为营业收入增长及经营亏损影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600037562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614011827","title":"百奥泰(688177.SH)2025年度归母净亏损3.36亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614011827","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614011827?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:42","pubTimestamp":1772098972,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰(688177.SH)披露2025年度业绩快报，2025年度实现营业收入9.34亿元，同比增长25.64%;归属于母公司所有者的净利润亏损3.36亿元，上年同期亏损5.1亿元。业绩变动主要原因是公司营业收入持续增长：一方面公司积极拓展市场，阿达木单抗注射液(格乐立®)和托珠单抗注射液(施瑞立®)销售额较上年同期稳步提升;另一方面本报告期公司乌司奴单抗注射液(STARJEMZA®)于美国上市销售，授权许可收入及销售收入增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613079727","title":"百奥泰(688177.SH)：达尔扑拜单抗注射液(BAT4406F)上市许可申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2613079727","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613079727?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:47","pubTimestamp":1771930078,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 百奥泰 发布公告，公司于近日收到国家药品监督管理局核准签发的关于公司在研药品达尔扑拜单抗注射液药品上市许可申请的《受理通知书》。截至本公告披露日，BAT4406F针对微小病变肾病/局灶节段性肾小球硬化适应症的一项II/III期注册临床研究正在全国多家三甲医院进行招募，该研究是我国首个针对该适应症的注册研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406767.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百奥泰(688177.SH)：达尔扑拜单抗注射液(BAT4406F)上市许可申请获得受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613797244","title":"百奥泰（688177）披露Gotenfia（戈利木单抗注射液）获欧洲EMA上市批准的公告，2月24日股价下跌0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613797244","media":"中金财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613797244?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:41","pubTimestamp":1771929669,"startTime":"0","endTime":"0","summary":"百奥泰生物制药股份有限公司近日披露公告，公司收到欧洲药品管理局通知，其开发的戈利木单抗注射液已获EMA上市批准。BAT2506是依据NMPA、FDA和EMA指导原则开发的生物类似药，目前上市申请已获NMPA、FDA及巴西国家卫生监督局受理。该批准有望对公司长期经营业绩产生积极影响，但未来可能面临激烈市场竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260224/32024193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["EMA","BK4081","BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778509215972,"stockEarnings":[{"period":"1week","weight":-0.0272},{"period":"1month","weight":-0.1351},{"period":"3month","weight":-0.1537},{"period":"6month","weight":-0.2292},{"period":"1year","weight":-0.0965},{"period":"ytd","weight":-0.134}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0463},{"period":"3month","weight":0.0281},{"period":"6month","weight":0.0456},{"period":"1year","weight":0.247},{"period":"ytd","weight":0.0532}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百奥泰生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9898人(较上一季度增加7.75%)","perCapita":"41834股","listingDate":"2020-02-21","address":"广东省广州市海珠区国际生物岛螺旋二路18号","registeredCapital":"41408万元","survey":" 百奥泰生物制药股份有限公司的主营业务是创新药和生物类似药的研发。公司的主要产品是自身免疫药物、抗肿瘤药物。公司被认定为国家高新技术企业、国家工业企业知识产权运用试点企业、国家知识产权优势企业、广东省新型研发机构、广东省工程技术研究中心、广东省工程实验室、广东省企业技术中心、广东省制造业单项冠军企业。","listedPrice":32.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百奥泰(688177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百奥泰(688177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百奥泰,688177,百奥泰股票,百奥泰股票老虎,百奥泰股票老虎国际,百奥泰行情,百奥泰股票行情,百奥泰股价,百奥泰股市,百奥泰股票价格,百奥泰股票交易,百奥泰股票购买,百奥泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百奥泰(688177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百奥泰(688177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}